

21. (Amended) A method of treating disorders of the central nervous system and/or of the immune system, comprising administering a therapeutically effective amount of a peptide according to claim 1 to a patient.

22. (Amended) A composition comprising a peptide according to claim 1 in combination with a physiologically acceptable carrier.

23. (Amended) A composition comprising two or more peptides according to claim 1 in combination with a physiologically acceptable carrier.

24. (Amended) A composition according to claim 22 in a form suitable for injection.

25. (Amended) A composition according to claim 22 in a form suitable for absorption through the mucosa of the oral/nasopharyngeal cavity and/or in a form suitable for absorption in the alimentary canal.

26. (Amended) A composition according to claim 22 in the form of a tablet, lozenge, gel, patch or plaster.

27. (Amended) A composition according to claim 22 in a form suitable for topical application.

28. (Amended) The use of a peptide according to claim 1 as a dietary supplement.

29. (Amended) The use of a peptide according to claim 1 as a dietary supplement for babies, small children, adults who have been subjected to chemotherapy and/or adults who have suffered from cachexia, or weight loss due to chronic disease.

30. (Amended) A dietary supplement comprising an orally ingestible combination of a peptide according to claim 1 combination with a physiologically acceptable.


31. (Amended) An antibody which binds to a peptide according to claim 1.

a2 32. (Amended) An antibody obtainable by using a peptide according to claim 1 as an antigen.

A copy of the claims showing the revisions is attached.

Respectfully submitted,

RANKIN, HILL, PORTER & CLARK LLP



Kenneth A. Clark
Reg. No. 32,119

925 Euclid Avenue
Suite 700
Cleveland, Ohio 44115-1405
(216) 566-9700

9\aat\12792\pa\2